JY
CTMX icon

Jeff Yass’s CytomX Therapeutics CTMX Stock Holding History

Jeff Yass’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.4M Buy
372,000
+69,500
+23% +$265K ﹤0.01% 7332
2026
Q1 		$1.42M Buy
302,500
+224,600
+288% +$1.14M ﹤0.01% 7025
2025
Q4 		$332K Sell
77,900
-86,100
-53% -$327K ﹤0.01% 9717
2025
Q3 		$523K Buy
164,000
+146,100
+816% +$329K ﹤0.01% 8832
2025
Q2 		$40.6K Buy
+17,900
New +$28.9K ﹤0.01% 12169
2024
Q3 		– Sell
-16,800
Closed -$20.5K – 12132
2024
Q2 		$20.5K Sell
16,800
-32,300
-66% -$64.3K ﹤0.01% 11662
2024
Q1 		$107K Buy
+49,100
New +$90.6K ﹤0.01% 11178
2022
Q1 		– Sell
-11,300
Closed -$49K – 13111
2021
Q4 		$49K Buy
+11,300
New +$66.2K ﹤0.01% 12554
2021
Q3 		– Sell
-18,900
Closed -$120K – 12824
2021
Q2 		$120K Buy
18,900
+1,000
+6% +$7.79K ﹤0.01% 11988
2021
Q1 		$138K Buy
17,900
+4,400
+33% +$34.8K ﹤0.01% 11702
2020
Q4 		$88K Buy
13,500
+2,900
+27% +$20.7K ﹤0.01% 10557
2020
Q3 		$70K Buy
+10,600
New +$78.6K ﹤0.01% 10090
2019
Q4 		– Sell
-10,900
Closed -$80K – 9826
2019
Q3 		$80K Buy
+10,900
New +$108K ﹤0.01% 9654
2019
Q1 		– Sell
-11,100
Closed -$168K – 8952
2018
Q4 		$168K Sell
11,100
-27,700
-71% -$411K ﹤0.01% 7893
2018
Q3 		$718K Buy
38,800
+9,900
+34% +$226K ﹤0.01% 5880
2018
Q2 		$661K Buy
+28,900
New +$738K ﹤0.01% 6244

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Jeff Yass's CTMX Position: Q2 2026 in Review

Jeff Yass reduced its CytomX Therapeutics (CTMX) stake by 95% in Q2 2026, selling an estimated $6.79M and leaving 90,673 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #10771.

Jeff Yass first reported a position in CTMX in Q4 2015 and has held it in 31 quarters since. The position peaked at $8.79M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Jeff Yass held 90,673 shares of CytomX Therapeutics worth $340K as of Q2 2026.
  • Jeff Yass sold 1,778,942 CytomX Therapeutics shares in Q2 2026, an estimated $6.79M.
  • CytomX Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10771 holding.
  • Jeff Yass first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 31 quarters since.
  • Jeff Yass's CytomX Therapeutics position peaked at $8.79M in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.